

Supplementary data

Supplementary Table 1. MitraScore.

<i>Variable</i>	<i>Points</i>
<i>Anemia</i>	<i>1 point</i>
<i>Glomerular filtrate rate <60 mL/min/1.73 m²</i>	<i>1 point</i>
<i>Left ventricular ejection fraction <40%</i>	<i>1 point</i>
<i>Peripheral artery disease</i>	<i>1 point</i>
<i>Chronic obstructive pulmonary disease</i>	<i>1 point</i>
<i>High diuretic dose</i>	<i>1 point</i>
<i>No therapy with renin-angiotensin system inhibitors</i>	<i>1 point</i>

Supplementary Table 2. Anatomic exclusion criteria of the EVEREST II trial.

Anatomic exclusion criteria of the EVEREST II trial

Primary regurgitant jet outside from A2 and P2 segments of the mitral valve

Leaflet flail Width ≥ 15 mm

Leaflet flail Gap ≥ 10 mm

Leaflet tethering with coaptation Length < 2 mm

Leaflet anatomy which may preclude clip implantation, proper clip positioning on the leaflets or sufficient reduction in MR

Evidence of calcification in the grasping area of the A2 and/or P2 scallops

Presence of a significant cleft of A2 or P2 scallops

Bileaflet flail or severe bileaflet prolapse (such as in Barlow disease)

Lack of both primary and secondary chordal support

Prior mitral valve leaflet surgery or any currently implanted mechanical prosthetic mitral valve

Mitral valve orifice area < 4.0 cm²

Echocardiographic evidence of intracardiac mass, thrombus or vegetation

Active endocarditis or active rheumatic heart disease or leaflets degenerated from rheumatic diseased

Primary regurgitant jet outside from A2 and P2 segments of the mitral valve

MR, mitral regurgitation.